nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Rosuvastatin—atherosclerosis	0.0904	0.148	CbGbCtD
Ponatinib—ABCB11—Pravastatin—atherosclerosis	0.0823	0.135	CbGbCtD
Ponatinib—ABCG2—Ezetimibe—atherosclerosis	0.043	0.0705	CbGbCtD
Ponatinib—ABCG2—Rosuvastatin—atherosclerosis	0.043	0.0705	CbGbCtD
Ponatinib—ABCG2—Pravastatin—atherosclerosis	0.0391	0.0642	CbGbCtD
Ponatinib—CYP3A5—Rosuvastatin—atherosclerosis	0.0238	0.0391	CbGbCtD
Ponatinib—CYP3A5—Simvastatin—atherosclerosis	0.0221	0.0363	CbGbCtD
Ponatinib—CYP3A5—Pravastatin—atherosclerosis	0.0217	0.0355	CbGbCtD
Ponatinib—CYP3A5—Lovastatin—atherosclerosis	0.0217	0.0355	CbGbCtD
Ponatinib—CYP2C8—Simvastatin—atherosclerosis	0.0213	0.0349	CbGbCtD
Ponatinib—CYP2C8—Lovastatin—atherosclerosis	0.0208	0.0342	CbGbCtD
Ponatinib—CYP2C8—Pravastatin—atherosclerosis	0.0208	0.0342	CbGbCtD
Ponatinib—CYP2D6—Niacin—atherosclerosis	0.0172	0.0282	CbGbCtD
Ponatinib—ABCB1—Ezetimibe—atherosclerosis	0.0155	0.0254	CbGbCtD
Ponatinib—ABCB1—Simvastatin—atherosclerosis	0.0144	0.0236	CbGbCtD
Ponatinib—ABCB1—Pravastatin—atherosclerosis	0.0141	0.0231	CbGbCtD
Ponatinib—ABCB1—Lovastatin—atherosclerosis	0.0141	0.0231	CbGbCtD
Ponatinib—CYP2D6—Simvastatin—atherosclerosis	0.0136	0.0223	CbGbCtD
Ponatinib—CYP2D6—Lovastatin—atherosclerosis	0.0133	0.0218	CbGbCtD
Ponatinib—CYP2D6—Pravastatin—atherosclerosis	0.0133	0.0218	CbGbCtD
Ponatinib—CYP3A4—Ezetimibe—atherosclerosis	0.00929	0.0152	CbGbCtD
Ponatinib—CYP3A4—Rosuvastatin—atherosclerosis	0.00929	0.0152	CbGbCtD
Ponatinib—CYP3A4—Simvastatin—atherosclerosis	0.00863	0.0142	CbGbCtD
Ponatinib—CYP3A4—Lovastatin—atherosclerosis	0.00845	0.0139	CbGbCtD
Ponatinib—CYP3A4—Pravastatin—atherosclerosis	0.00845	0.0139	CbGbCtD
Ponatinib—FGFR3—appendage—atherosclerosis	0.00582	0.0691	CbGeAlD
Ponatinib—PDGFRA—penis—atherosclerosis	0.00511	0.0607	CbGeAlD
Ponatinib—KDR—umbilical vein—atherosclerosis	0.0038	0.0451	CbGeAlD
Ponatinib—KDR—hindlimb—atherosclerosis	0.00348	0.0413	CbGeAlD
Ponatinib—KDR—appendage—atherosclerosis	0.00299	0.0355	CbGeAlD
Ponatinib—Nilotinib—MAPK8—atherosclerosis	0.00268	0.439	CrCbGaD
Ponatinib—TEK—artery—atherosclerosis	0.00261	0.031	CbGeAlD
Ponatinib—FGFR4—connective tissue—atherosclerosis	0.00244	0.0289	CbGeAlD
Ponatinib—SRC—artery—atherosclerosis	0.00232	0.0275	CbGeAlD
Ponatinib—TEK—endothelium—atherosclerosis	0.00221	0.0262	CbGeAlD
Ponatinib—KDR—artery—atherosclerosis	0.00213	0.0253	CbGeAlD
Ponatinib—TEK—blood vessel—atherosclerosis	0.00203	0.0241	CbGeAlD
Ponatinib—SRC—endothelium—atherosclerosis	0.00196	0.0233	CbGeAlD
Ponatinib—SRC—blood vessel—atherosclerosis	0.00181	0.0215	CbGeAlD
Ponatinib—KDR—endothelium—atherosclerosis	0.0018	0.0214	CbGeAlD
Ponatinib—Nilotinib—CSF1R—atherosclerosis	0.00175	0.286	CrCbGaD
Ponatinib—LYN—connective tissue—atherosclerosis	0.00167	0.0198	CbGeAlD
Ponatinib—KDR—blood vessel—atherosclerosis	0.00166	0.0197	CbGeAlD
Ponatinib—FGFR3—connective tissue—atherosclerosis	0.00166	0.0197	CbGeAlD
Ponatinib—KIT—endothelium—atherosclerosis	0.0016	0.019	CbGeAlD
Ponatinib—KIT—blood vessel—atherosclerosis	0.00147	0.0175	CbGeAlD
Ponatinib—Imatinib—CSF1R—atherosclerosis	0.00146	0.239	CrCbGaD
Ponatinib—FLT3—connective tissue—atherosclerosis	0.00143	0.0169	CbGeAlD
Ponatinib—FGFR4—liver—atherosclerosis	0.00131	0.0156	CbGeAlD
Ponatinib—FLT3—cardiovascular system—atherosclerosis	0.00124	0.0147	CbGeAlD
Ponatinib—RET—connective tissue—atherosclerosis	0.00114	0.0136	CbGeAlD
Ponatinib—BCR—adipose tissue—atherosclerosis	0.0011	0.0131	CbGeAlD
Ponatinib—FGFR2—connective tissue—atherosclerosis	0.00109	0.0129	CbGeAlD
Ponatinib—TEK—connective tissue—atherosclerosis	0.00104	0.0124	CbGeAlD
Ponatinib—FGFR1—adipose tissue—atherosclerosis	0.000982	0.0117	CbGeAlD
Ponatinib—FGFR2—cardiovascular system—atherosclerosis	0.000947	0.0112	CbGeAlD
Ponatinib—PDGFRA—connective tissue—atherosclerosis	0.000945	0.0112	CbGeAlD
Ponatinib—SRC—connective tissue—atherosclerosis	0.000927	0.011	CbGeAlD
Ponatinib—TEK—cardiovascular system—atherosclerosis	0.000907	0.0108	CbGeAlD
Ponatinib—LYN—liver—atherosclerosis	0.000899	0.0107	CbGeAlD
Ponatinib—FGFR3—liver—atherosclerosis	0.000894	0.0106	CbGeAlD
Ponatinib—LCK—adipose tissue—atherosclerosis	0.000878	0.0104	CbGeAlD
Ponatinib—KDR—connective tissue—atherosclerosis	0.000852	0.0101	CbGeAlD
Ponatinib—FGFR2—adipose tissue—atherosclerosis	0.000835	0.00991	CbGeAlD
Ponatinib—PDGFRA—cardiovascular system—atherosclerosis	0.000822	0.00976	CbGeAlD
Ponatinib—SRC—cardiovascular system—atherosclerosis	0.000806	0.00957	CbGeAlD
Ponatinib—TEK—adipose tissue—atherosclerosis	0.0008	0.0095	CbGeAlD
Ponatinib—BCR—liver—atherosclerosis	0.000774	0.00919	CbGeAlD
Ponatinib—FLT3—liver—atherosclerosis	0.000768	0.00912	CbGeAlD
Ponatinib—KIT—connective tissue—atherosclerosis	0.000755	0.00897	CbGeAlD
Ponatinib—KDR—cardiovascular system—atherosclerosis	0.000742	0.0088	CbGeAlD
Ponatinib—PDGFRA—adipose tissue—atherosclerosis	0.000725	0.00861	CbGeAlD
Ponatinib—SRC—adipose tissue—atherosclerosis	0.000711	0.00844	CbGeAlD
Ponatinib—FGFR1—liver—atherosclerosis	0.000688	0.00817	CbGeAlD
Ponatinib—ABL1—connective tissue—atherosclerosis	0.000658	0.00781	CbGeAlD
Ponatinib—KIT—cardiovascular system—atherosclerosis	0.000657	0.0078	CbGeAlD
Ponatinib—KDR—adipose tissue—atherosclerosis	0.000654	0.00776	CbGeAlD
Ponatinib—LCK—liver—atherosclerosis	0.000616	0.00731	CbGeAlD
Ponatinib—ABCB11—liver—atherosclerosis	0.000602	0.00714	CbGeAlD
Ponatinib—FGFR2—liver—atherosclerosis	0.000585	0.00695	CbGeAlD
Ponatinib—KIT—adipose tissue—atherosclerosis	0.00058	0.00688	CbGeAlD
Ponatinib—ABL1—cardiovascular system—atherosclerosis	0.000572	0.00679	CbGeAlD
Ponatinib—TEK—liver—atherosclerosis	0.000561	0.00666	CbGeAlD
Ponatinib—Nasopharyngitis—Pravastatin—atherosclerosis	0.000541	0.00435	CcSEcCtD
Ponatinib—Infestation—Ezetimibe—atherosclerosis	0.000541	0.00435	CcSEcCtD
Ponatinib—Infestation NOS—Ezetimibe—atherosclerosis	0.000541	0.00435	CcSEcCtD
Ponatinib—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00054	0.00435	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Simvastatin—atherosclerosis	0.000537	0.00433	CcSEcCtD
Ponatinib—Urinary tract infection—Lovastatin—atherosclerosis	0.000536	0.00431	CcSEcCtD
Ponatinib—Abdominal distension—Niacin—atherosclerosis	0.000535	0.0043	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.000534	0.00429	CcSEcCtD
Ponatinib—Erectile dysfunction—Simvastatin—atherosclerosis	0.000533	0.00429	CcSEcCtD
Ponatinib—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00053	0.00427	CcSEcCtD
Ponatinib—Jaundice—Ezetimibe—atherosclerosis	0.000527	0.00424	CcSEcCtD
Ponatinib—Abdominal distension—Pravastatin—atherosclerosis	0.000526	0.00424	CcSEcCtD
Ponatinib—Arrhythmia—Rosuvastatin—atherosclerosis	0.000522	0.0042	CcSEcCtD
Ponatinib—Angina pectoris—Niacin—atherosclerosis	0.000517	0.00416	CcSEcCtD
Ponatinib—Pancreatitis—Pravastatin—atherosclerosis	0.000513	0.00413	CcSEcCtD
Ponatinib—Mental disorder—Rosuvastatin—atherosclerosis	0.000512	0.00412	CcSEcCtD
Ponatinib—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000511	0.00412	CcSEcCtD
Ponatinib—Angina pectoris—Pravastatin—atherosclerosis	0.000509	0.0041	CcSEcCtD
Ponatinib—PDGFRA—liver—atherosclerosis	0.000508	0.00604	CbGeAlD
Ponatinib—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000505	0.00407	CcSEcCtD
Ponatinib—ABL1—adipose tissue—atherosclerosis	0.000505	0.00599	CbGeAlD
Ponatinib—Jaundice—Simvastatin—atherosclerosis	0.000503	0.00404	CcSEcCtD
Ponatinib—SRC—liver—atherosclerosis	0.000499	0.00592	CbGeAlD
Ponatinib—Erectile dysfunction—Niacin—atherosclerosis	0.000489	0.00394	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.000486	0.00391	CcSEcCtD
Ponatinib—Erectile dysfunction—Pravastatin—atherosclerosis	0.000482	0.00388	CcSEcCtD
Ponatinib—Oedema peripheral—Ezetimibe—atherosclerosis	0.000478	0.00385	CcSEcCtD
Ponatinib—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000477	0.00384	CcSEcCtD
Ponatinib—Weight decreased—Pravastatin—atherosclerosis	0.000473	0.00381	CcSEcCtD
Ponatinib—Jaundice—Niacin—atherosclerosis	0.000461	0.00371	CcSEcCtD
Ponatinib—Stomatitis—Niacin—atherosclerosis	0.000461	0.00371	CcSEcCtD
Ponatinib—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00046	0.0037	CcSEcCtD
Ponatinib—Flushing—Lovastatin—atherosclerosis	0.000459	0.0037	CcSEcCtD
Ponatinib—KDR—liver—atherosclerosis	0.000459	0.00544	CbGeAlD
Ponatinib—Myocardial infarction—Pravastatin—atherosclerosis	0.000457	0.00368	CcSEcCtD
Ponatinib—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000457	0.00368	CcSEcCtD
Ponatinib—Jaundice—Pravastatin—atherosclerosis	0.000454	0.00366	CcSEcCtD
Ponatinib—Urinary tract infection—Pravastatin—atherosclerosis	0.000453	0.00365	CcSEcCtD
Ponatinib—Flushing—Ezetimibe—atherosclerosis	0.00045	0.00363	CcSEcCtD
Ponatinib—Chills—Lovastatin—atherosclerosis	0.000444	0.00357	CcSEcCtD
Ponatinib—Cough—Rosuvastatin—atherosclerosis	0.000444	0.00357	CcSEcCtD
Ponatinib—Angiopathy—Ezetimibe—atherosclerosis	0.00044	0.00354	CcSEcCtD
Ponatinib—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000437	0.00352	CcSEcCtD
Ponatinib—Alopecia—Lovastatin—atherosclerosis	0.000437	0.00352	CcSEcCtD
Ponatinib—Myalgia—Rosuvastatin—atherosclerosis	0.000433	0.00348	CcSEcCtD
Ponatinib—Arthralgia—Rosuvastatin—atherosclerosis	0.000433	0.00348	CcSEcCtD
Ponatinib—Flushing—Simvastatin—atherosclerosis	0.00043	0.00346	CcSEcCtD
Ponatinib—Alopecia—Ezetimibe—atherosclerosis	0.000429	0.00345	CcSEcCtD
Ponatinib—Haemoglobin—Niacin—atherosclerosis	0.000427	0.00344	CcSEcCtD
Ponatinib—Mental disorder—Ezetimibe—atherosclerosis	0.000425	0.00342	CcSEcCtD
Ponatinib—Haemorrhage—Niacin—atherosclerosis	0.000425	0.00342	CcSEcCtD
Ponatinib—Hypoaesthesia—Niacin—atherosclerosis	0.000423	0.0034	CcSEcCtD
Ponatinib—Erythema—Ezetimibe—atherosclerosis	0.000423	0.0034	CcSEcCtD
Ponatinib—Malnutrition—Ezetimibe—atherosclerosis	0.000423	0.0034	CcSEcCtD
Ponatinib—Oedema peripheral—Niacin—atherosclerosis	0.000419	0.00337	CcSEcCtD
Ponatinib—Back pain—Lovastatin—atherosclerosis	0.000417	0.00335	CcSEcCtD
Ponatinib—Hypoaesthesia—Pravastatin—atherosclerosis	0.000416	0.00335	CcSEcCtD
Ponatinib—Chills—Simvastatin—atherosclerosis	0.000415	0.00334	CcSEcCtD
Ponatinib—Muscle spasms—Lovastatin—atherosclerosis	0.000414	0.00333	CcSEcCtD
Ponatinib—Infection—Rosuvastatin—atherosclerosis	0.000412	0.00332	CcSEcCtD
Ponatinib—Visual impairment—Niacin—atherosclerosis	0.00041	0.0033	CcSEcCtD
Ponatinib—Alopecia—Simvastatin—atherosclerosis	0.000409	0.00329	CcSEcCtD
Ponatinib—Back pain—Ezetimibe—atherosclerosis	0.000409	0.00329	CcSEcCtD
Ponatinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000407	0.00327	CcSEcCtD
Ponatinib—KIT—liver—atherosclerosis	0.000406	0.00482	CbGeAlD
Ponatinib—Muscle spasms—Ezetimibe—atherosclerosis	0.000406	0.00327	CcSEcCtD
Ponatinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000406	0.00327	CcSEcCtD
Ponatinib—Vision blurred—Lovastatin—atherosclerosis	0.000406	0.00327	CcSEcCtD
Ponatinib—Mental disorder—Simvastatin—atherosclerosis	0.000406	0.00326	CcSEcCtD
Ponatinib—Visual impairment—Pravastatin—atherosclerosis	0.000403	0.00325	CcSEcCtD
Ponatinib—Erythema—Simvastatin—atherosclerosis	0.000403	0.00324	CcSEcCtD
Ponatinib—ABCB1—blood vessel—atherosclerosis	0.000399	0.00473	CbGeAlD
Ponatinib—Eye disorder—Niacin—atherosclerosis	0.000397	0.0032	CcSEcCtD
Ponatinib—Flushing—Niacin—atherosclerosis	0.000394	0.00317	CcSEcCtD
Ponatinib—Anaemia—Ezetimibe—atherosclerosis	0.000391	0.00314	CcSEcCtD
Ponatinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000388	0.00313	CcSEcCtD
Ponatinib—Flushing—Pravastatin—atherosclerosis	0.000388	0.00313	CcSEcCtD
Ponatinib—Muscle spasms—Simvastatin—atherosclerosis	0.000387	0.00312	CcSEcCtD
Ponatinib—Angiopathy—Niacin—atherosclerosis	0.000386	0.0031	CcSEcCtD
Ponatinib—Leukopenia—Lovastatin—atherosclerosis	0.000386	0.0031	CcSEcCtD
Ponatinib—Chills—Niacin—atherosclerosis	0.000381	0.00307	CcSEcCtD
Ponatinib—Vision blurred—Simvastatin—atherosclerosis	0.00038	0.00306	CcSEcCtD
Ponatinib—Arrhythmia—Niacin—atherosclerosis	0.00038	0.00306	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000378	0.00304	CcSEcCtD
Ponatinib—Alopecia—Niacin—atherosclerosis	0.000376	0.00302	CcSEcCtD
Ponatinib—Chills—Pravastatin—atherosclerosis	0.000375	0.00302	CcSEcCtD
Ponatinib—Insomnia—Rosuvastatin—atherosclerosis	0.000375	0.00302	CcSEcCtD
Ponatinib—Arrhythmia—Pravastatin—atherosclerosis	0.000374	0.00301	CcSEcCtD
Ponatinib—Paraesthesia—Rosuvastatin—atherosclerosis	0.000373	0.003	CcSEcCtD
Ponatinib—Anaemia—Simvastatin—atherosclerosis	0.000372	0.003	CcSEcCtD
Ponatinib—Malnutrition—Niacin—atherosclerosis	0.00037	0.00298	CcSEcCtD
Ponatinib—Erythema—Niacin—atherosclerosis	0.00037	0.00298	CcSEcCtD
Ponatinib—Alopecia—Pravastatin—atherosclerosis	0.00037	0.00298	CcSEcCtD
Ponatinib—Cough—Ezetimibe—atherosclerosis	0.000369	0.00297	CcSEcCtD
Ponatinib—Arthralgia—Lovastatin—atherosclerosis	0.000367	0.00295	CcSEcCtD
Ponatinib—Myalgia—Lovastatin—atherosclerosis	0.000367	0.00295	CcSEcCtD
Ponatinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000365	0.00294	CcSEcCtD
Ponatinib—Hypertension—Ezetimibe—atherosclerosis	0.000365	0.00294	CcSEcCtD
Ponatinib—Leukopenia—Simvastatin—atherosclerosis	0.000361	0.0029	CcSEcCtD
Ponatinib—Myalgia—Ezetimibe—atherosclerosis	0.00036	0.00289	CcSEcCtD
Ponatinib—Arthralgia—Ezetimibe—atherosclerosis	0.00036	0.00289	CcSEcCtD
Ponatinib—Dry mouth—Lovastatin—atherosclerosis	0.000359	0.00289	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000357	0.00287	CcSEcCtD
Ponatinib—Muscle spasms—Niacin—atherosclerosis	0.000356	0.00286	CcSEcCtD
Ponatinib—Pain—Rosuvastatin—atherosclerosis	0.000355	0.00285	CcSEcCtD
Ponatinib—Constipation—Rosuvastatin—atherosclerosis	0.000355	0.00285	CcSEcCtD
Ponatinib—ABL1—liver—atherosclerosis	0.000354	0.0042	CbGeAlD
Ponatinib—Dry mouth—Ezetimibe—atherosclerosis	0.000352	0.00283	CcSEcCtD
Ponatinib—Muscle spasms—Pravastatin—atherosclerosis	0.00035	0.00282	CcSEcCtD
Ponatinib—Infection—Lovastatin—atherosclerosis	0.000349	0.00281	CcSEcCtD
Ponatinib—Vision blurred—Niacin—atherosclerosis	0.000349	0.00281	CcSEcCtD
Ponatinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000344	0.00277	CcSEcCtD
Ponatinib—Vision blurred—Pravastatin—atherosclerosis	0.000343	0.00276	CcSEcCtD
Ponatinib—Myalgia—Simvastatin—atherosclerosis	0.000343	0.00276	CcSEcCtD
Ponatinib—Arthralgia—Simvastatin—atherosclerosis	0.000343	0.00276	CcSEcCtD
Ponatinib—Infection—Ezetimibe—atherosclerosis	0.000343	0.00276	CcSEcCtD
Ponatinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000339	0.00273	CcSEcCtD
Ponatinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000338	0.00272	CcSEcCtD
Ponatinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000338	0.00272	CcSEcCtD
Ponatinib—Anaemia—Pravastatin—atherosclerosis	0.000337	0.00271	CcSEcCtD
Ponatinib—Skin disorder—Ezetimibe—atherosclerosis	0.000335	0.0027	CcSEcCtD
Ponatinib—Leukopenia—Niacin—atherosclerosis	0.000331	0.00267	CcSEcCtD
Ponatinib—Oedema—Simvastatin—atherosclerosis	0.000329	0.00265	CcSEcCtD
Ponatinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000328	0.00264	CcSEcCtD
Ponatinib—Infection—Simvastatin—atherosclerosis	0.000327	0.00263	CcSEcCtD
Ponatinib—Leukopenia—Pravastatin—atherosclerosis	0.000326	0.00262	CcSEcCtD
Ponatinib—Cough—Niacin—atherosclerosis	0.000323	0.0026	CcSEcCtD
Ponatinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000322	0.00259	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00032	0.00258	CcSEcCtD
Ponatinib—ABCG2—adipose tissue—atherosclerosis	0.000318	0.00378	CbGeAlD
Ponatinib—Insomnia—Lovastatin—atherosclerosis	0.000318	0.00256	CcSEcCtD
Ponatinib—Cough—Pravastatin—atherosclerosis	0.000318	0.00256	CcSEcCtD
Ponatinib—Paraesthesia—Lovastatin—atherosclerosis	0.000316	0.00254	CcSEcCtD
Ponatinib—Arthralgia—Niacin—atherosclerosis	0.000315	0.00253	CcSEcCtD
Ponatinib—Myalgia—Niacin—atherosclerosis	0.000315	0.00253	CcSEcCtD
Ponatinib—Hypertension—Pravastatin—atherosclerosis	0.000315	0.00253	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000314	0.00253	CcSEcCtD
Ponatinib—Dyspnoea—Lovastatin—atherosclerosis	0.000313	0.00252	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000313	0.00252	CcSEcCtD
Ponatinib—Insomnia—Ezetimibe—atherosclerosis	0.000312	0.00251	CcSEcCtD
Ponatinib—Arthralgia—Pravastatin—atherosclerosis	0.00031	0.0025	CcSEcCtD
Ponatinib—Myalgia—Pravastatin—atherosclerosis	0.00031	0.0025	CcSEcCtD
Ponatinib—Paraesthesia—Ezetimibe—atherosclerosis	0.00031	0.00249	CcSEcCtD
Ponatinib—Dyspepsia—Lovastatin—atherosclerosis	0.000309	0.00249	CcSEcCtD
Ponatinib—Dry mouth—Niacin—atherosclerosis	0.000308	0.00248	CcSEcCtD
Ponatinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000307	0.00247	CcSEcCtD
Ponatinib—Decreased appetite—Lovastatin—atherosclerosis	0.000306	0.00246	CcSEcCtD
Ponatinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000304	0.00244	CcSEcCtD
Ponatinib—Fatigue—Lovastatin—atherosclerosis	0.000303	0.00244	CcSEcCtD
Ponatinib—Oedema—Niacin—atherosclerosis	0.000302	0.00243	CcSEcCtD
Ponatinib—Pain—Lovastatin—atherosclerosis	0.000301	0.00242	CcSEcCtD
Ponatinib—Constipation—Lovastatin—atherosclerosis	0.000301	0.00242	CcSEcCtD
Ponatinib—Decreased appetite—Ezetimibe—atherosclerosis	0.0003	0.00241	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.0003	0.00241	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000298	0.0024	CcSEcCtD
Ponatinib—Asthenia—Rosuvastatin—atherosclerosis	0.000298	0.0024	CcSEcCtD
Ponatinib—Insomnia—Simvastatin—atherosclerosis	0.000297	0.00239	CcSEcCtD
Ponatinib—Oedema—Pravastatin—atherosclerosis	0.000297	0.00239	CcSEcCtD
Ponatinib—Fatigue—Ezetimibe—atherosclerosis	0.000297	0.00239	CcSEcCtD
Ponatinib—Infection—Pravastatin—atherosclerosis	0.000295	0.00238	CcSEcCtD
Ponatinib—CYP3A5—adipose tissue—atherosclerosis	0.000295	0.00351	CbGeAlD
Ponatinib—Paraesthesia—Simvastatin—atherosclerosis	0.000295	0.00238	CcSEcCtD
Ponatinib—Pain—Ezetimibe—atherosclerosis	0.000295	0.00237	CcSEcCtD
Ponatinib—Constipation—Ezetimibe—atherosclerosis	0.000295	0.00237	CcSEcCtD
Ponatinib—Pruritus—Rosuvastatin—atherosclerosis	0.000294	0.00236	CcSEcCtD
Ponatinib—Skin disorder—Niacin—atherosclerosis	0.000293	0.00236	CcSEcCtD
Ponatinib—Dyspnoea—Simvastatin—atherosclerosis	0.000293	0.00236	CcSEcCtD
Ponatinib—Hyperhidrosis—Niacin—atherosclerosis	0.000292	0.00235	CcSEcCtD
Ponatinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000291	0.00234	CcSEcCtD
Ponatinib—Dyspepsia—Simvastatin—atherosclerosis	0.000289	0.00233	CcSEcCtD
Ponatinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000287	0.00231	CcSEcCtD
Ponatinib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000287	0.00231	CcSEcCtD
Ponatinib—Decreased appetite—Simvastatin—atherosclerosis	0.000286	0.0023	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000284	0.00228	CcSEcCtD
Ponatinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000284	0.00228	CcSEcCtD
Ponatinib—Fatigue—Simvastatin—atherosclerosis	0.000284	0.00228	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000282	0.00227	CcSEcCtD
Ponatinib—Pain—Simvastatin—atherosclerosis	0.000281	0.00226	CcSEcCtD
Ponatinib—Constipation—Simvastatin—atherosclerosis	0.000281	0.00226	CcSEcCtD
Ponatinib—Abdominal pain—Lovastatin—atherosclerosis	0.000278	0.00224	CcSEcCtD
Ponatinib—Body temperature increased—Lovastatin—atherosclerosis	0.000278	0.00224	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000275	0.00221	CcSEcCtD
Ponatinib—Dizziness—Rosuvastatin—atherosclerosis	0.000274	0.00221	CcSEcCtD
Ponatinib—Insomnia—Niacin—atherosclerosis	0.000273	0.0022	CcSEcCtD
Ponatinib—Abdominal pain—Ezetimibe—atherosclerosis	0.000273	0.00219	CcSEcCtD
Ponatinib—Body temperature increased—Ezetimibe—atherosclerosis	0.000273	0.00219	CcSEcCtD
Ponatinib—Paraesthesia—Niacin—atherosclerosis	0.000271	0.00218	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000271	0.00218	CcSEcCtD
Ponatinib—Dyspnoea—Niacin—atherosclerosis	0.000269	0.00217	CcSEcCtD
Ponatinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000269	0.00216	CcSEcCtD
Ponatinib—Insomnia—Pravastatin—atherosclerosis	0.000269	0.00216	CcSEcCtD
Ponatinib—Paraesthesia—Pravastatin—atherosclerosis	0.000267	0.00215	CcSEcCtD
Ponatinib—Dyspepsia—Niacin—atherosclerosis	0.000266	0.00214	CcSEcCtD
Ponatinib—Dyspnoea—Pravastatin—atherosclerosis	0.000265	0.00213	CcSEcCtD
Ponatinib—Decreased appetite—Niacin—atherosclerosis	0.000262	0.00211	CcSEcCtD
Ponatinib—Dyspepsia—Pravastatin—atherosclerosis	0.000262	0.00211	CcSEcCtD
Ponatinib—Rash—Rosuvastatin—atherosclerosis	0.000262	0.00211	CcSEcCtD
Ponatinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000261	0.0021	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000261	0.0021	CcSEcCtD
Ponatinib—Body temperature increased—Simvastatin—atherosclerosis	0.00026	0.00209	CcSEcCtD
Ponatinib—Abdominal pain—Simvastatin—atherosclerosis	0.00026	0.00209	CcSEcCtD
Ponatinib—Headache—Rosuvastatin—atherosclerosis	0.00026	0.00209	CcSEcCtD
Ponatinib—Decreased appetite—Pravastatin—atherosclerosis	0.000258	0.00208	CcSEcCtD
Ponatinib—Pain—Niacin—atherosclerosis	0.000258	0.00208	CcSEcCtD
Ponatinib—Fatigue—Pravastatin—atherosclerosis	0.000256	0.00206	CcSEcCtD
Ponatinib—Constipation—Pravastatin—atherosclerosis	0.000254	0.00205	CcSEcCtD
Ponatinib—Pain—Pravastatin—atherosclerosis	0.000254	0.00205	CcSEcCtD
Ponatinib—Asthenia—Lovastatin—atherosclerosis	0.000252	0.00203	CcSEcCtD
Ponatinib—Pruritus—Lovastatin—atherosclerosis	0.000249	0.002	CcSEcCtD
Ponatinib—Asthenia—Ezetimibe—atherosclerosis	0.000247	0.00199	CcSEcCtD
Ponatinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000247	0.00199	CcSEcCtD
Ponatinib—Nausea—Rosuvastatin—atherosclerosis	0.000246	0.00198	CcSEcCtD
Ponatinib—Pruritus—Ezetimibe—atherosclerosis	0.000244	0.00196	CcSEcCtD
Ponatinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000243	0.00196	CcSEcCtD
Ponatinib—Diarrhoea—Lovastatin—atherosclerosis	0.000241	0.00194	CcSEcCtD
Ponatinib—Body temperature increased—Niacin—atherosclerosis	0.000239	0.00192	CcSEcCtD
Ponatinib—Abdominal pain—Niacin—atherosclerosis	0.000239	0.00192	CcSEcCtD
Ponatinib—Asthenia—Simvastatin—atherosclerosis	0.000236	0.0019	CcSEcCtD
Ponatinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000236	0.0019	CcSEcCtD
Ponatinib—Abdominal pain—Pravastatin—atherosclerosis	0.000235	0.00189	CcSEcCtD
Ponatinib—Body temperature increased—Pravastatin—atherosclerosis	0.000235	0.00189	CcSEcCtD
Ponatinib—Pruritus—Simvastatin—atherosclerosis	0.000233	0.00187	CcSEcCtD
Ponatinib—Dizziness—Lovastatin—atherosclerosis	0.000232	0.00187	CcSEcCtD
Ponatinib—CYP2C8—liver—atherosclerosis	0.000229	0.00272	CbGeAlD
Ponatinib—Dizziness—Ezetimibe—atherosclerosis	0.000228	0.00184	CcSEcCtD
Ponatinib—Diarrhoea—Simvastatin—atherosclerosis	0.000225	0.00181	CcSEcCtD
Ponatinib—Vomiting—Lovastatin—atherosclerosis	0.000224	0.0018	CcSEcCtD
Ponatinib—ABCG2—liver—atherosclerosis	0.000223	0.00265	CbGeAlD
Ponatinib—Rash—Lovastatin—atherosclerosis	0.000222	0.00178	CcSEcCtD
Ponatinib—Dermatitis—Lovastatin—atherosclerosis	0.000221	0.00178	CcSEcCtD
Ponatinib—Headache—Lovastatin—atherosclerosis	0.00022	0.00177	CcSEcCtD
Ponatinib—Imatinib—ALB—atherosclerosis	0.00022	0.036	CrCbGaD
Ponatinib—Vomiting—Ezetimibe—atherosclerosis	0.000219	0.00176	CcSEcCtD
Ponatinib—Dizziness—Simvastatin—atherosclerosis	0.000217	0.00175	CcSEcCtD
Ponatinib—Rash—Ezetimibe—atherosclerosis	0.000217	0.00175	CcSEcCtD
Ponatinib—Dermatitis—Ezetimibe—atherosclerosis	0.000217	0.00175	CcSEcCtD
Ponatinib—Asthenia—Niacin—atherosclerosis	0.000217	0.00174	CcSEcCtD
Ponatinib—Headache—Ezetimibe—atherosclerosis	0.000216	0.00174	CcSEcCtD
Ponatinib—Pruritus—Niacin—atherosclerosis	0.000214	0.00172	CcSEcCtD
Ponatinib—Asthenia—Pravastatin—atherosclerosis	0.000213	0.00172	CcSEcCtD
Ponatinib—Pruritus—Pravastatin—atherosclerosis	0.00021	0.00169	CcSEcCtD
Ponatinib—Vomiting—Simvastatin—atherosclerosis	0.000209	0.00168	CcSEcCtD
Ponatinib—Nausea—Lovastatin—atherosclerosis	0.000209	0.00168	CcSEcCtD
Ponatinib—Rash—Simvastatin—atherosclerosis	0.000207	0.00167	CcSEcCtD
Ponatinib—Dermatitis—Simvastatin—atherosclerosis	0.000207	0.00167	CcSEcCtD
Ponatinib—CYP3A5—liver—atherosclerosis	0.000207	0.00246	CbGeAlD
Ponatinib—Diarrhoea—Niacin—atherosclerosis	0.000207	0.00166	CcSEcCtD
Ponatinib—Headache—Simvastatin—atherosclerosis	0.000206	0.00166	CcSEcCtD
Ponatinib—Nausea—Ezetimibe—atherosclerosis	0.000205	0.00165	CcSEcCtD
Ponatinib—Diarrhoea—Pravastatin—atherosclerosis	0.000203	0.00164	CcSEcCtD
Ponatinib—Dizziness—Niacin—atherosclerosis	0.0002	0.00161	CcSEcCtD
Ponatinib—Dizziness—Pravastatin—atherosclerosis	0.000197	0.00158	CcSEcCtD
Ponatinib—Nausea—Simvastatin—atherosclerosis	0.000195	0.00157	CcSEcCtD
Ponatinib—Vomiting—Niacin—atherosclerosis	0.000192	0.00155	CcSEcCtD
Ponatinib—Rash—Niacin—atherosclerosis	0.00019	0.00153	CcSEcCtD
Ponatinib—Dermatitis—Niacin—atherosclerosis	0.00019	0.00153	CcSEcCtD
Ponatinib—Headache—Niacin—atherosclerosis	0.000189	0.00152	CcSEcCtD
Ponatinib—Vomiting—Pravastatin—atherosclerosis	0.000189	0.00152	CcSEcCtD
Ponatinib—Rash—Pravastatin—atherosclerosis	0.000187	0.00151	CcSEcCtD
Ponatinib—Dermatitis—Pravastatin—atherosclerosis	0.000187	0.00151	CcSEcCtD
Ponatinib—Headache—Pravastatin—atherosclerosis	0.000186	0.0015	CcSEcCtD
Ponatinib—Nausea—Niacin—atherosclerosis	0.000179	0.00144	CcSEcCtD
Ponatinib—ABCB1—cardiovascular system—atherosclerosis	0.000178	0.00211	CbGeAlD
Ponatinib—Nausea—Pravastatin—atherosclerosis	0.000177	0.00142	CcSEcCtD
Ponatinib—ABCB1—adipose tissue—atherosclerosis	0.000157	0.00186	CbGeAlD
Ponatinib—CYP3A4—liver—atherosclerosis	0.000155	0.00185	CbGeAlD
Ponatinib—CYP2D6—liver—atherosclerosis	0.000153	0.00182	CbGeAlD
Ponatinib—ABCB1—liver—atherosclerosis	0.00011	0.00131	CbGeAlD
Ponatinib—SRC—Signaling Pathways—PDGFB—atherosclerosis	3.67e-06	2.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—atherosclerosis	3.65e-06	2.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NFKB1—atherosclerosis	3.64e-06	2.07e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BGN—atherosclerosis	3.64e-06	2.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—atherosclerosis	3.64e-06	2.07e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—atherosclerosis	3.63e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—atherosclerosis	3.62e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOS3—atherosclerosis	3.62e-06	2.06e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA5—atherosclerosis	3.61e-06	2.05e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—atherosclerosis	3.59e-06	2.04e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK8—atherosclerosis	3.58e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGT—atherosclerosis	3.58e-06	2.03e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CG—atherosclerosis	3.58e-06	2.03e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—atherosclerosis	3.56e-06	2.03e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOB—atherosclerosis	3.56e-06	2.02e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCA1—atherosclerosis	3.55e-06	2.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—atherosclerosis	3.54e-06	2.01e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—atherosclerosis	3.53e-06	2.01e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—atherosclerosis	3.51e-06	1.99e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LEP—atherosclerosis	3.51e-06	1.99e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NFKB1—atherosclerosis	3.5e-06	1.99e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—atherosclerosis	3.48e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—atherosclerosis	3.48e-06	1.98e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—atherosclerosis	3.48e-06	1.98e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CAV1—atherosclerosis	3.47e-06	1.98e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	3.47e-06	1.97e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOA1—atherosclerosis	3.47e-06	1.97e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARA—atherosclerosis	3.47e-06	1.97e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—atherosclerosis	3.46e-06	1.97e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—atherosclerosis	3.46e-06	1.97e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK8—atherosclerosis	3.45e-06	1.96e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKB1—atherosclerosis	3.44e-06	1.96e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—atherosclerosis	3.44e-06	1.95e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—atherosclerosis	3.43e-06	1.95e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—atherosclerosis	3.4e-06	1.93e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—LPL—atherosclerosis	3.4e-06	1.93e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—INS—atherosclerosis	3.38e-06	1.92e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK8—atherosclerosis	3.38e-06	1.92e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—atherosclerosis	3.36e-06	1.91e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALOX5—atherosclerosis	3.35e-06	1.91e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ESR1—atherosclerosis	3.35e-06	1.9e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—atherosclerosis	3.34e-06	1.9e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—atherosclerosis	3.33e-06	1.89e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—atherosclerosis	3.31e-06	1.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—F2—atherosclerosis	3.31e-06	1.88e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—atherosclerosis	3.3e-06	1.88e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—atherosclerosis	3.29e-06	1.87e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—atherosclerosis	3.29e-06	1.87e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—atherosclerosis	3.27e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—atherosclerosis	3.27e-06	1.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKB1—atherosclerosis	3.27e-06	1.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKB1—atherosclerosis	3.26e-06	1.85e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAV1—atherosclerosis	3.26e-06	1.85e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOA1—atherosclerosis	3.25e-06	1.85e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—atherosclerosis	3.24e-06	1.84e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CD36—atherosclerosis	3.23e-06	1.84e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKB1—atherosclerosis	3.23e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—atherosclerosis	3.21e-06	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—atherosclerosis	3.21e-06	1.83e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—atherosclerosis	3.21e-06	1.82e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—atherosclerosis	3.2e-06	1.82e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—atherosclerosis	3.2e-06	1.82e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—atherosclerosis	3.18e-06	1.81e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—atherosclerosis	3.17e-06	1.8e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—atherosclerosis	3.17e-06	1.8e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—atherosclerosis	3.16e-06	1.8e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—atherosclerosis	3.16e-06	1.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—atherosclerosis	3.15e-06	1.79e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—atherosclerosis	3.14e-06	1.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—atherosclerosis	3.14e-06	1.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—atherosclerosis	3.14e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK3—atherosclerosis	3.13e-06	1.78e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—atherosclerosis	3.12e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	3.11e-06	1.77e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOB—atherosclerosis	3.1e-06	1.76e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—atherosclerosis	3.09e-06	1.76e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—atherosclerosis	3.09e-06	1.75e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—atherosclerosis	3.08e-06	1.75e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—atherosclerosis	3.08e-06	1.75e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—atherosclerosis	3.06e-06	1.74e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—atherosclerosis	3.05e-06	1.73e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—atherosclerosis	3.02e-06	1.72e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—atherosclerosis	3.02e-06	1.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—atherosclerosis	3.01e-06	1.71e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	3.01e-06	1.71e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARA—atherosclerosis	3e-06	1.71e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—INS—atherosclerosis	3e-06	1.7e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LIPC—atherosclerosis	2.99e-06	1.7e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOC3—atherosclerosis	2.97e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—atherosclerosis	2.97e-06	1.69e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	2.97e-06	1.69e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—atherosclerosis	2.96e-06	1.69e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—LPL—atherosclerosis	2.96e-06	1.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	2.96e-06	1.68e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—atherosclerosis	2.96e-06	1.68e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LDLR—atherosclerosis	2.95e-06	1.68e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—atherosclerosis	2.95e-06	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—atherosclerosis	2.95e-06	1.68e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—atherosclerosis	2.94e-06	1.67e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—atherosclerosis	2.93e-06	1.66e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	2.93e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—atherosclerosis	2.93e-06	1.66e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOB—atherosclerosis	2.92e-06	1.66e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—atherosclerosis	2.92e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—atherosclerosis	2.92e-06	1.66e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—atherosclerosis	2.92e-06	1.66e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—atherosclerosis	2.91e-06	1.65e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—atherosclerosis	2.9e-06	1.65e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—atherosclerosis	2.9e-06	1.65e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—atherosclerosis	2.9e-06	1.65e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—atherosclerosis	2.9e-06	1.65e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—atherosclerosis	2.89e-06	1.64e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—atherosclerosis	2.89e-06	1.64e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CETP—atherosclerosis	2.88e-06	1.64e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKB1—atherosclerosis	2.87e-06	1.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—atherosclerosis	2.87e-06	1.63e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—atherosclerosis	2.86e-06	1.63e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—atherosclerosis	2.85e-06	1.62e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—atherosclerosis	2.85e-06	1.62e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—atherosclerosis	2.84e-06	1.62e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—atherosclerosis	2.83e-06	1.61e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAV1—atherosclerosis	2.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOA1—atherosclerosis	2.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CD36—atherosclerosis	2.81e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—INS—atherosclerosis	2.81e-06	1.6e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—atherosclerosis	2.8e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—atherosclerosis	2.8e-06	1.59e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	2.8e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—atherosclerosis	2.79e-06	1.59e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—LPL—atherosclerosis	2.79e-06	1.59e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—atherosclerosis	2.79e-06	1.58e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—atherosclerosis	2.78e-06	1.58e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—atherosclerosis	2.77e-06	1.57e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.76e-06	1.57e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SERPINE1—atherosclerosis	2.75e-06	1.56e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—atherosclerosis	2.72e-06	1.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—atherosclerosis	2.72e-06	1.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	2.71e-06	1.54e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—atherosclerosis	2.7e-06	1.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—atherosclerosis	2.69e-06	1.53e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—atherosclerosis	2.68e-06	1.52e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—atherosclerosis	2.67e-06	1.52e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CD36—atherosclerosis	2.65e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—atherosclerosis	2.63e-06	1.5e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—atherosclerosis	2.63e-06	1.49e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARA—atherosclerosis	2.61e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—atherosclerosis	2.61e-06	1.48e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.61e-06	1.48e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—atherosclerosis	2.58e-06	1.47e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—atherosclerosis	2.58e-06	1.46e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—atherosclerosis	2.57e-06	1.46e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—atherosclerosis	2.57e-06	1.46e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—atherosclerosis	2.57e-06	1.46e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—atherosclerosis	2.56e-06	1.46e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—atherosclerosis	2.56e-06	1.45e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—atherosclerosis	2.53e-06	1.44e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.51e-06	1.43e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—atherosclerosis	2.48e-06	1.41e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—atherosclerosis	2.48e-06	1.41e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—atherosclerosis	2.48e-06	1.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—atherosclerosis	2.47e-06	1.4e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARA—atherosclerosis	2.46e-06	1.4e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—atherosclerosis	2.46e-06	1.4e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAV1—atherosclerosis	2.46e-06	1.4e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOA1—atherosclerosis	2.45e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—INS—atherosclerosis	2.43e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—atherosclerosis	2.39e-06	1.36e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—atherosclerosis	2.39e-06	1.36e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—atherosclerosis	2.39e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—atherosclerosis	2.38e-06	1.35e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKB1—atherosclerosis	2.36e-06	1.34e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—atherosclerosis	2.34e-06	1.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—atherosclerosis	2.33e-06	1.32e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.32e-06	1.32e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAV1—atherosclerosis	2.32e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—atherosclerosis	2.32e-06	1.32e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOA1—atherosclerosis	2.31e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—atherosclerosis	2.29e-06	1.3e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	2.25e-06	1.28e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.24e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—atherosclerosis	2.23e-06	1.27e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—atherosclerosis	2.2e-06	1.25e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—atherosclerosis	2.16e-06	1.23e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—atherosclerosis	2.16e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—atherosclerosis	2.14e-06	1.22e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—atherosclerosis	2.13e-06	1.21e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—INS—atherosclerosis	2.12e-06	1.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—atherosclerosis	2.12e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—atherosclerosis	2.11e-06	1.2e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.11e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—atherosclerosis	2.11e-06	1.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—atherosclerosis	2.11e-06	1.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKB1—atherosclerosis	2.09e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—atherosclerosis	2.05e-06	1.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	2.05e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—atherosclerosis	2.04e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—atherosclerosis	2.03e-06	1.15e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—atherosclerosis	2.02e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—atherosclerosis	2.02e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—INS—atherosclerosis	2e-06	1.14e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.99e-06	1.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—atherosclerosis	1.99e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—atherosclerosis	1.96e-06	1.12e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—atherosclerosis	1.95e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—atherosclerosis	1.95e-06	1.11e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—atherosclerosis	1.94e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOB—atherosclerosis	1.91e-06	1.09e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—atherosclerosis	1.89e-06	1.08e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—atherosclerosis	1.89e-06	1.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	1.89e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—atherosclerosis	1.87e-06	1.06e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—atherosclerosis	1.87e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—atherosclerosis	1.86e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.86e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—atherosclerosis	1.83e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—LPL—atherosclerosis	1.82e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—atherosclerosis	1.8e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—atherosclerosis	1.79e-06	1.02e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—atherosclerosis	1.78e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—atherosclerosis	1.75e-06	9.96e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—atherosclerosis	1.74e-06	9.88e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD36—atherosclerosis	1.73e-06	9.85e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—atherosclerosis	1.72e-06	9.8e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—atherosclerosis	1.7e-06	9.67e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—atherosclerosis	1.66e-06	9.46e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.64e-06	9.34e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARA—atherosclerosis	1.61e-06	9.16e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.6e-06	9.11e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—atherosclerosis	1.58e-06	8.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—atherosclerosis	1.56e-06	8.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—atherosclerosis	1.53e-06	8.69e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAV1—atherosclerosis	1.51e-06	8.61e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOA1—atherosclerosis	1.51e-06	8.59e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—atherosclerosis	1.48e-06	8.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.38e-06	7.84e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—atherosclerosis	1.36e-06	7.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—atherosclerosis	1.33e-06	7.57e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—atherosclerosis	1.31e-06	7.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—INS—atherosclerosis	1.31e-06	7.42e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—atherosclerosis	1.21e-06	6.87e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—atherosclerosis	1.2e-06	6.81e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—atherosclerosis	1.15e-06	6.51e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—atherosclerosis	1.13e-06	6.44e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.05e-06	5.95e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—atherosclerosis	9.81e-07	5.58e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—atherosclerosis	8.55e-07	4.86e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—atherosclerosis	8.05e-07	4.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—atherosclerosis	5.26e-07	2.99e-06	CbGpPWpGaD
